Analysis
Open Access
Is Canada missing out? An assessment of drugs approved internationally between 2016 and 2020 and not submitted for Health Canada review
Étienne Gaudette, Shirin Rizzardo, Sasha B. Wladyka, Tuhin Rahman and Kevin R. Pothier
CMAJ June 12, 2023 195 (23) E815-E820; DOI: https://doi.org/10.1503/cmaj.230339
Étienne Gaudette
Institute of Health Policy Management and Evaluation (Gaudette), University of Toronto, Toronto, Ont.; Patented Medicine Prices Review Board (Gaudette, Rizzardo, Wladyka, Rahman, Pothier), Ottawa, Ont.
PhDShirin Rizzardo
Institute of Health Policy Management and Evaluation (Gaudette), University of Toronto, Toronto, Ont.; Patented Medicine Prices Review Board (Gaudette, Rizzardo, Wladyka, Rahman, Pothier), Ottawa, Ont.
RPh MScSasha B. Wladyka
Institute of Health Policy Management and Evaluation (Gaudette), University of Toronto, Toronto, Ont.; Patented Medicine Prices Review Board (Gaudette, Rizzardo, Wladyka, Rahman, Pothier), Ottawa, Ont.
MBA MScTuhin Rahman
Institute of Health Policy Management and Evaluation (Gaudette), University of Toronto, Toronto, Ont.; Patented Medicine Prices Review Board (Gaudette, Rizzardo, Wladyka, Rahman, Pothier), Ottawa, Ont.
MAKevin R. Pothier
Institute of Health Policy Management and Evaluation (Gaudette), University of Toronto, Toronto, Ont.; Patented Medicine Prices Review Board (Gaudette, Rizzardo, Wladyka, Rahman, Pothier), Ottawa, Ont.
BSc Pharm RPh![Loading Loading](https://www.cmaj.ca/sites/all/modules/contrib/panels_ajax_tab/images/loading.gif)
Data supplements
Online appendix
Related Articles
- Gaudette, É., Rizzardo, S., Wladyka, S. B., Rahman, T., & Pothier, K. R. (2023). Le Canada manque-t-il le bateau? Un inventaire des médicaments approuvés à l’international entre 2016 et 2020 qui n’ont pas été soumis à Santé Canada. CMAJ, 195(34), E1161-E1167. Accessed July 16, 2024. https://doi.org/10.1503/cmaj.230339-f.
In this issue
Article tools
Respond to this article
Is Canada missing out? An assessment of drugs approved internationally between 2016 and 2020 and not submitted for Health Canada review
Étienne Gaudette, Shirin Rizzardo, Sasha B. Wladyka, Tuhin Rahman, Kevin R. Pothier
CMAJ Jun 2023, 195 (23) E815-E820; DOI: 10.1503/cmaj.230339
Jump to section
- Article
- Of new drugs approved in the US and Europe, how many do not come to Canada?
- What kinds of new active substances are not submitted for approval in Canada?
- How widely marketed in peer countries are the new active substances not submitted to Health Canada?
- Should people in Canada be worried about access to innovative drugs?
- Footnotes
- References
- Figures & Tables
- Related Content
- Responses
- Metrics